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Abstract
To explore the mechanisms underlying the suggested role of the vitamin D/vitamin D receptor (VDR) complex in the
pathogenesis of obesity we performed genetic and immunologic analyses in obese and non-obese Saudi individuals
without other concomitant chronic diseases. Genomic DNA was genotyped for gene single nucleotide polymorphisms
(SNPs) of VDR by allelic discrimination in 402 obese (body mass index –BMI$30 kg/m2) and 489 non-obese (BMI,30 kg/
m2) Saudis. Q-PCR analyses were performed using an ABI Prism 7000 Sequence Detection System. The inflammosome
pathway was analysed by PCR, cytokines and plasma lipopolysaccaride (LPS) concentrations with ELISA assays. Results
showed that the VDR SNPs rs731236 (G) (TaqI) and rs1544410 (T) (Bsm-I) minor allele polymorphisms are significantly more
frequent in obese individuals (p = 0.009, b= 0.086 and p= 0.028, b= 0.072, respectively). VDR haplotypes identified are
positively (GTA) (p = 0.008, b= 1.560); or negatively (ACC) (p = 0.044, b= 0.766) associated with obesity and higher BMI
scores. The GTA "risk" haplotype was characterized by an up-regulation of inflammosome components, a higher production
of proinflammatory cytokines (p,0.05) and a lower VDR expression. Plasma LPS concentration was also increased in GTA
obese individuals (p,0.05), suggesting an alteration of gut permeability leading to microbial translocation. Data herein
indicate that polymorphisms affecting the vitamin D/VDR axis play a role in obesity that is associated with an ongoing
degree of inflammation, possibly resulting from alterations of gut permeability and microbial translocation. These results
could help the definition of VDR fingerprints that predict an increased risk of developing obesity and might contribute to
the identification of novel therapeutic strategies for this metabolic condition.
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Introduction
Obesity is a complex disease that affects over 500 million people
worldwide and whose incidence increased substantially in the past
3 decades [1]. The prevalence of this disease differs in diverse
zones of the world and peaks in countries such as Saudi Arabia,
where 34% of adults are obese [2]. Obesity is associated with
premature death due to an increased risk of a number of chronic
conditions including type 2 Diabetes Mellitus (T2DM) and
cardiovascular disease [3–4], and is correlated with an ongoing
degree of low grade inflammation [5].
The pathogenesis of this disease is complex and includes genetic
and environmental factors that are not yet fully clarified. Vitamin
D is a good candidate to play a role in obesity as evidenced by
epidemiologic, genetic and metabolic data [6–8]. The action of
this vitamin is mediated through vitamin D receptor (VDR), a
nuclear transcription-regulating factor that drives the synthesis of
proteins involved in bone mineral homeostasis and cell cycle
regulation. Vitamin D is a seco-steroid hormone ingested in the
diet or synthesized in the skin when 7-dehydrocolesterol reacts
with UVB ultraviolet light. The biologically inert vitamin D3 is
hydroxylated in the liver and in the kidney into (1,25(OH)2D).
This form becomes active upon binding to the vitamin D receptor
(VDR). Thus, given the metabolic pathway of vitamin D synthesis
and action, this compound can be described as an environmental
factor (diet, UVB light) whose metabolic effects are influenced by
the genetic background (genetic variance of VDR). One of the
main evidence for a role of VDR in obesity was derived from
transgenic mice studies that over-express human VDR in
adipocytes which leads to a marked decreases in energy
expenditure and induction of obesity [9,10].
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Besides being involved in the pathogenesis of obesity, the
vitamin D/VDR axis also modulates inflammation. In vitro
studies showed that VDR agonists decrease pro- inflammatory
cytokine production by human blood mononuclear cells [11], and
that pretreatment of rat peritoneal cells with 1,25 (OH)2D3 inhibits
high glucose- and lipopolysaccaride (LPS)-induced tumor necrosis
factor alpha (TNFa) as well as tumor growth factor beta (TGFb)
release [12]. Recent results indicate that the down regulation of
VDR expression by siRNA leads to an increased production of
pro-inflammatory cytokines by human adipocytes [13]. These
effects are possibly mediated by the modulation of the inflammo-
some, a multiprotein complex expressed in myeloid cells that is
part of the innate immune response. The inflammosome includes
a cascade of proteins whose activation results in the production of
inflammatory cytokines including interleukin 1b (IL1b) and IL18.
Even acute inflammation in adipose tissues was suggested to lead
to changes in the number and the quality of stromal cells, a
phenomenon known as "adipose tissue remodeling" [14].
The VDR gene contains several polymorphisms, including
three single nucleotide polymorphisms (SNPs) located near the 39
un-translated region (39 UTR) (Taq1, Bsm1, and Apa1) identified by
their restriction endonuclease sites [15]. Although not functional,
these SNPs are linked with a poly (A) microsatellite repeat in the 39
UTR that could influence VDR mRNA stability [16]. Given the
metabolic pathway of vitamin D synthesis and action, this
compound can be described as an environmental factor whose
metabolic effects are influenced genetically.
We investigated possible associations of the three known VDR
SNPs rs731236(A/G)(TaqI), rs1544410(C/T)(BsmI) and
rs7975232 (A/C)(ApaI) with obesity in a population from Saudi
Arabia, a country where obesity is reaching endemic proportions
[2]. As VDR modulates inflammation, which in turn is observed in
obesity, we verified whether the VDR SNPs that are more
common in obese individuals would be associated with an up-
regulation of inflammosome-related proteins and cytokines.
Results herein reinforce the concept that the vitamin D/VDR
axis plays a role in obesity which is at least partially mediated by
an ongoing degree of inflammation.
Results
VDR polymorphisms in obese individuals
Analyses of possible association of VDR minor allele polymor-
phisms with BMI were performed in 891 Saudi subjects (402
obese, 489 lean) through a linear regression analysis considering
BMI as the independent variable, and gender and age as
covariates. The association of these variables with obesity and
BMI was indicated by b positive values. Variables (including age
and VDR minor alleles) with a positive b value are associated with
higher BMI, therefore to a higher risk of obesity after adjustment
for all the other covariates. Conversely, b values less than zero
were associated with lower BMI scores and identify individuals
with a lower risk to develop obesity (in case they are not obese) or
are overweight. Results of these analyses showed that the VDR
rs731236 (G) and VDR rs1544410 (T) alleles were positively
associated with BMI and these alleles were associated with obesity
independent of age and sex (p=0.009, b=0.086 and p=0.028,
b=0.072 respectively) (Table 1).
Haplotype association with obesity was evaluated by verifying
the distribution of VDR haplotypes in obese vs. lean subjects.
Results showed that the VDR rs731236 (G)/rs1544410 (T)/
rs7975232 (A)(GTA) haplotype was more frequent in obese
individuals, whereas the complementary rs731236 (A)/rs1544410
(C)/rs7975232(C)(ACC) haplotype was more common in lean
subjects (Table 2).
Haplotype stratification by BMI values was calculated next by
linear regression analyses in the total group of subjects adjusted for
age and sex. A statistically significant association was detected
between the VDR GTA haplotype and positive b values
(p=0.008, b=1.560). This haplotype is thus associated with a
higher risk of obesity and higher BMI scores. Notably, the
complementary ACC haplotype was negatively associated with
BMI (p=0.044, b=20.766) (Table 2). The ACC haplotype,
therefore, was significantly associated with lack of obesity in non-
obese individuals and with lower BMI scores in obese subjects.
Inflammosome pathway expression
The inflammosome pathway was evaluated in cells of obese and
non-obese individuals who were characterized by the presence of
the ‘‘protective’’ (ACC) or the ‘‘risk’’ (GTA) VDR haplotypes; cells
were stimulated with LPS. Results obtained in non-obese
individuals carrying the ACC VDR haplotype were used as the
baseline value. An increased expression of genes within the
inflammosome pathway was observed in GTA non-obese as well
as in both ACC and GTA obese individuals, but the up regulation
was significantly more marked in obese individuals with the GTA
‘‘risk’’ haplotype (Figure 1). Within this VDR haplotype, mRNA
expression for a number of genes, including the inflammosome
components (NAIP, CASP5, NLRP3), Nod-like receptors (NAIP,
NLRX1, NOD1, NLRC5 NLRP3, NLRP4, NLRP5 NLRP9),
downstream signaling (P2RX7, PANX1, RIPk2, TIRAP, NFKB1)
and effector molecules (IL12b, IL18, IL1b, IL33, PTGS2 CCL5,
CCL7, IL6, TNF, IFNb) was increased in obese individuals
carrying the GTA ‘‘risk’’ haplotype.
Pro-inflammatory cytokine production
Activation of the inflammosome results in the down-stream
production of a number of proinflammatory cytokines. The higher
inflammatory response observed in individuals carrying the GTA
‘‘risk’’ VDR haplotype was further confirmed by ELISA analyses
showing that IL1b, IL6, TNFa and IL18 production by LPS-
stimulated PBMC was significantly increased (p,0.05) by cells of
obese individuals carrying this haplotype (Figure 2).
Plasma LPS concentration
Plasma LPS concentration is a marker of altered gut barrier
permeability and has been reported to be associated with increased
inflammation in obesity. Obese individuals carrying the ‘‘at-risk’’
VDR GTA genotype showed higher LPS plasma concentrations
than obese subjects with the ‘‘protective’’ ACC haplotype (p,
0.05) suggesting a correlation between obesity and microbial
translocation that could be responsible for the maintenance of the
inflammatory state at systemic level (Figure 3).
VDR gene expression
Finally, the possible effect of the GTA ‘‘risk’’ and the ACC
‘‘protective’’ VDR haplotypes on the expression of the VDR gene
was analyzed. Results indicated the presence of a slight but
consistent decrease in VDR expression was associated with GTA
‘‘risk’’ (0.917 (95%) IC: 0.416-2.054) as compared to the ACC
‘‘protective’’ (1.265 (95%) IC:0. 587-2.239) haplotype (Figure S1).
Discussion
In the attempt to shed light on the complex relationship
between the vitamin D/VDR axis, metabolic diseases and
inflammation we performed genetic and immunologic analyses
VDR Polymorphisms versus Obesity in Saudi
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on a group of individuals enrolled in the RIYADH COHORT, a
longitudinal epidemiologic study that is ongoing in Riyadh, the
capital city of the Kingdom of Saudi Arabia. Results of these
analyses showed that VDR polymorphisms located in 39 haplotype
block region of VDR gene correlate with obesity development.
Furthermore, VDR haplotypes that are associated with statistically
increased or reduced risks of obesity and with higher/lower BMI
scores could be identified. Notably, genes that are part of the
inflammosome complex, and cytokines that are the end product of
the activation of such complex, were significantly up regulated in
cells carrying the VDR haplotype that correlates with an increased
risk of obesity and higher BMI scores; associated with such ‘‘at
risk’’ VDR haplotype was also an increased plasma concentration
of LPS and a reduced expression of VDR.
Analysis of possible associations between VDR polymorphisms
and obesity showed the presence of a strong association of the
rs731236 (G) and rs1544410 (T) VDR minor alleles with higher
BMI values independently of age and sex. In particular haplotype
segregation analyses revealed the presence of a significantly higher
risk of obesity and increased BMI in individuals carrying the GTA
(rs731236 (G), rs1544410 (T), rs7975232 (A)) haplotype, whereas
the complementary ACC (rs731236 (A), rs1544410(C),
rs7975232(C)) haplotype was associated to a reduced risk of
obesity and lower BMI scores, possibly suggesting a protective
role. Once ‘‘risk’’ and ‘‘protective VDR haplotypes were identified
we focused the subsequent part of the analyses on examining
whether these haplotypes would have been associated with a
different degree of inflammation. Results indicated that the VDR
GTA ‘‘risk’’ haplotype is indeed correlated with a more robust up
regulation of a number of key proteins that take part in the
inflammosome activity, resulting in a significantly increased
production of proinflmammatory cytokines; this same ‘‘risk’’
genotype was also correlated with a lower expression of VDR
mRNA. These results suggest that two different genetic types of
obesity that could be differentiated based on VDR haplotypes
might exist: a more severe form that is associated with higher BMI
scores and a more relevant degree of inflammation, and a less
important one that may not correlate with an important
inflammatory status. Notably, a subgroup of obese individuals
has been described who does not display the typical metabolic
disorders associated with obesity. These individuals are defined as
metabolic healthy obese (MHO) do not have insulin resistance,
lipid disorders, or hypertension and are hypothesized to have
lower risk of obesity-related complications [18,19]. It will be
Table 1. VDR polymorphisms association with BMI scores.
t p value b 95% CI
Model 1 23.39 ,0.001 27.87 21.75–25.05
Age 6.46 ,0.001 0.212 0.08–0.15
Gender 22.26 0.024 20.074 22.05–20.15
rs731236(G) 2.625 0.009 0.086 0.33–2.29
Model 2 28.35 ,0.001 23.59 21.95–25.22
Age 6.41 ,0.001 0.211 20.08–20.15
Gender 22.25 0.025 20.074 22.04–20.14
rs1544410(T) 2.20 0.028 0.072 0.12–2.06
Model 3 24.93 ,0.001 23.41 21.56–25.25
Selected Variables Age 6.36 ,0.001 0.21 0.08–0.15
Gender 22.26 0.024 20.074 22.05–21.14
rs7975232(A) 1.67 0.095 0.055 20.18–2.30
Linear regression analyses were used to compare the VDR genotypes adjusted for the co-variants age and gender. Significance was set at p,0.05. Responsible variable:
BMI scores, covariates: age and gender (female vs male). Model 1: VDR rs731236(G):AG/GG vs. AA; Model 2: VDR rs1544410(T): CT/TT vs. CC; Model 3: VDR
rs7975232(A):AC/AA vs. CC.
doi:10.1371/journal.pone.0102141.t001
Table 2. VDR Haplotype distribution. Percentage frequencies are reported; VDR Haplotype association with linear BMI accounting
for age and gender
Haplotype Obese% Lean% P-value Linear BMI association
b Stat P-value
ATC 0.6 0.2 - 20.873 1.63 0.202
ACC 36.0 38.0 0.227 20.766 3.90 0.044
GTA 40.4 36.3 0.075 1.56 7.09 0.008
ATA 1.5 2.4 - 0.172 0.04 0.831
GCA 2.6 3.6 0.604 0.352 0.776 0.379
ACA 18.7 19.3 0.677 20.438 0.73 0.393
Order of SNPs: rs731236, rs1544410, rs7975232. Pearson‘s p value, beta risk and statistic were calculated by Haplotype analysis.
doi:10.1371/journal.pone.0102141.t002
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interesting to verify whether the GTA ‘‘protective’’ haplotype is
predominant in these individuals.
It has been convincingly shown that the vitamin D/VDR axis
modulates the activity of the immune system, and that in turn the
immune system plays a pivotal role in vitamin D metabolism
[20,21]. Different reports suggest that chronic inflammation is a
key marker of obesity, the origin of inflammation during obesity
and the underlying molecular mechanisms that explain its
occurrence are nevertheless not fully understood. The importance
of inflammation in obesity was analyzed in the animal model.
Thus, recent data show that NLRP3-/- knockout mice do not
increase weight when fed a high fat diet, and that elimination of
NLRP3 expression prevents obesity-induced caspase-1 cleavage as
well as IL1b and IL18 activation [22]. These results suggest a
direct involvement of NLRP3-inflammosome in obesity, and are
reinforced by results herein indicating that the VDR GTA ‘‘risk’’
haplotype correlates with a higher inflammatory response to LPS.
mRNA expression for a number of genes, including those of the
Figure 1. Expression of 96 genes involved in the inflammosome pathway assessed by real-time quantitative RT-PCR in obese and
non-obese subjects carrying the VDR ‘‘at-risk’’ (GTA) or the ‘‘protective’’ (ACC) haplotype. Following LPS stimulation the expression of
genes within the inflammosome pathway is significantly more increased in obese individuals with the GTA ‘‘risk’’ haplotype. Results are shown as
fold-change expression compared to the ACC non obese controls assumed as baseline expression level. Only the targets showing different expression
levels in the different groups are shown.
doi:10.1371/journal.pone.0102141.g001
Figure 2. IL1b, IL6 (panel A) IL18 and TNFa (panel B) production assessed by multiplex ELISA in supernatant of LPS stimulated
PBMC isolated from obese individuals carrying the VDR ‘‘at-risk’’ (GTA)(black bars) or the ‘‘protective’’ (ACC)(white bars)
haplotype. Results are shown as mean values fold-change expression from the unstimulated sample 6 standard error.
doi:10.1371/journal.pone.0102141.g002
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inflammosome component downstream signaling and effector
molecules was indeed significantly augmented in GTA obese
individuals. These results were further confirmed by quantification
of proinflammatory cytokines (IL1b, IL18, TNFa and IL-6) in
LPS-stimulated cell cultures, suggesting that the degree of
inflammation is directly correlated to obesity.
Plasmatic LPS concentration, a marker of altered gut barrier
permeability, was also increased in GTA obese individuals. LPS
binds to TLR4, a molecule expressed on the surface of a number
of different immune cells. Recent results indicate that obesity-
associated inflammation, besides being driven by dietary factors
and nutrients such as glucose and lipids, is mediated by LPS
[23,24]. Indeed, fat deposition compromises intestinal permeabil-
ity, liver function and the ability of Kuppfer cells to adsorb
endotoxin [25,26], whose circulating concentration is, therefore,
increased. This in turn, mediates chronic low-grade of inflamma-
tion through the activation of TLR and the inflammosome
pathway to exacerbate the insulin resistant state [27–30]. In
agreement with these observation LPS plasma concentration was
increased in obese individuals carrying the ‘‘at-risk’’ GTA
genotype, suggesting a correlation between obesity and microbial
translocation that could be responsible for the maintenance of the
inflammatory state at systemic level. Increased systemic LPS
concentrations are seen in HIV-infected individuals and are
possibly responsible for the chronic inflammation that character-
izes this condition [31–33].
Results obtained in in vitro systems indicate that the release of
proinflammatory cytokines by human PBMC and rat peritoneal
mesothelial cells is reduced by VDR agonists [10–12]. Recent data
also indicate that the siRNA-induced down regulation of VDR
expression results in an increased production of such cytokines by
human adipocytes [13]. In this light it is interesting to note that a
slight but consistent reduction of VDR expression was detected in
cells that were characterized by the presence of the GTA ‘‘risk’’
haplotype. Thus the inflammation seen in the GTA haplotype
could be the result of a different modulation of VDR expression,
reinforcing the hypothesis of an additive effect of environmental
and genetic factors in determining BMI [34].
In conclusion, results herein reinforce the idea that the vitamin
D/VDR axis plays a role in the pathogenesis of obesity that is
dependent on the presence of particular SNP and is at least in part
mediated by an ongoing degree of inflammation, possibly
secondarily to microbial translocation. Understanding the mech-
anism underlying the inflammation that is associated with obesity
could contribute to the identification of novel therapeutic
strategies to prevent or treat this metabolic condition.
Materials and Methods
Patients and controls
Eight hundred-ninety one Saudi individuals were enrolled in the
study; 402 of these subjects (45%) (239 males, 163 females; mean
age: 42.7610.4) were frankly obese (BMI $30kg/m2) and 489
(263 males, 226 females; mean age 36.4615.2) were non-obese. A
group of 87 subjects (47 males and 37 females; mean age
34.87613.1) were classified as overweight (BMI = 25-29.9 kg/m2)
[17]. However this borderline group was too small to be
considered as a separate group. These individuals are part of the
Biomarker Screening in Riyadh Project (RIYADH COHORT), a
capital-wide epidemiologic study taken from over ,17,000
consenting Saudis coming from different Primary Health Care
Centers (PHCCs). In brief, subjects were recruited from their
homes using a random cluster sampling strategy. Consenting
participants were then requested to visit the nearest participating
PHCC for questionnaire administration, anthropometric mea-
surement and blood extraction.
A questionnaire focusing on demographic information and past
medical history was given to all subjects. Those with co-
morbidities that needed medical attention or with medical
complications (coronary artery disease, diabetes mellitus type 2,
nephropathy, thyroid diseases and end stage renal or liver disease)
were excluded from the study. Anthropometry included measure-
ment of height (to the nearest 0.5 cm) and weight (to the nearest
0.1 kg); BMI was calculated as kg/m2. Written consent was
obtained and ethics approval was granted by the Ethics
Committee of the College of Science Research Center, King
Saud University, Riyadh, Kingdom of Saudi Arabia (KSA).
Figure 3. Plasma LPS concentration in obese subjects carrying the VDR ‘‘at-risk’’ (GTA) (black bars) or the ‘‘protective’’ (ACC) (white
bars) haplotype. Mean values 6 standard error is shown.
doi:10.1371/journal.pone.0102141.g003
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VDR SNP analysis
Genomic DNA of all the enrolled subjects was isolated from
200 ml of frozen whole blood collected in EDTA-containing tubes
by using the Illustra blood genomic prep minispin kit (GE
Healthcare Europe GMBH, Freiburg, Germany). VDR SNPs
(rs731236, rs1544410, rs7975232) were evaluated by allelic
discrimination Real-time PCR using pre-designed TaqMan
probes (Applied Biosystems, Foster City, CA, USA). The PCR
consisted of a hot start at 95uC for 10 minutes followed by 40
cycles of 94uC for 15 seconds and 60uC for 1 minute. Fluorescence
detection takes place at a temperature of 60uC. All assays were
performed in 10 ml reactions, using TaqMan Genotyping Master
Mix on 96-well plates using an ABI 7000 instrument (Applied
Biosystems). Control samples representing all possible genotypes
and a negative control were included in each reaction.
VDR gene expression
Total RNA was extracted from 1.5 ml fresh blood (collected
from 56 healthy subjects unrelated with patients enrolled in the
study) and processed within an hour after collection, and cDNA
samples were prepared as previously described (18)VDR gene Q-
PCR experiments were performed in 96-well plates using an ABI
Prism 7000 Sequence Detection System (Applied Biosystems) and
a pre-made TaqMan probe (assay ID: Hs_01045840_m1). Three
housekeeping genes (GAPDH, ACTB, YWHAZ) were used for
normalization (assay IDs: Hs_99999905_m1, Hs_99999903_m1
and Hs_03044281_g1 respectively). Amplification efficiencies of
target and reference genes assessment was carried out before any
calculation of expression using the REST software (http://gene-
quantification.com). Serial dilutions in triplets of a pool of 20
cDNAs were used for each transcript (VDR, YWHAZ, GAPDH,
ACTB). The software determines the slope with a logarithmic
algorithm as well as an indication of the linearity of logarithmic
alignment using Pearson’s correlation coefficient. The efficiency
(E) is in the range from 1 (minimum value) to 2 (theoretical
maximum and optimum) and is calculated from the slope,
according to the equation E=10 [-1/slope]. Real-time relative
expression experiments were performed according to manufac-
turer’s instructions. Briefly, 1 ml of cDNA was used in a final PCR
reaction volume of 20 ml containing 10 ml of gene expression
master mix, 8 ml of water and 2 ml of TaqMan probe. PCR cycles
were as follows: 10 min at 95uC followed by 40 cycles of 15uC at
95uC and 1 min at 60uC. All reactions were performed in
triplicate, with non-template control for each gene and one inter-
run calibrator that removes the technical run-to-run variation
between samples analyzed in different runs.
Inflammosome-pathway analyses
One x 106 peripheral blood mononuclear cells (PBMC) isolated
from 28 obese (VDR haplotypes: 14 GTA and 14 ACC) and 28
non-obese volunteers (VDR haplotypes: 14 GTA and 14 ACC)
were incubated for either 3 (mRNA expression) or 24 hours
(protein expression) with medium alone or in the presence of
2 mg/ml LPS. RNA was extracted using the acid guanidium
thiocyanate–phenol–chloroform method, dissolved in RNase-free
water, and purified from genomic DNA with RNase-free DNase
(New England Biolabs, Ipswich, USA). One microgram of RNA
was reverse transcribed into first-strand cDNA in a 20 ml final
volume containing 1 mM random hexanucleotide primers, 1 mM
oligo dT and 200U Moloney murine leukemia virus reverse
transcriptase (Clontech, Palo Alto, California, USA).
The inflammosome pathway was analysed in LPS-stimulated
cells using a PCR array including a set of optimized real-time PCR
primers on 96-well plates (SABiosciences Corporation, Frederick,
MD, USA). This approach allows the monitoring of mRNA
expression of 84 genes related to the inflammosome-pathway
activation, plus five housekeeping genes, following the procedures
suggested by the manufacturer. Controls are included in each
array for genomic DNA contamination, RNA quality, and general
PCR performance. Experiments were run on individuals pooled
into 4 different groups each including 14 subjects: ACC obese,
GTA obese, ACC non obese and GTA non obese. Results
represent the mean value of the different targets analysed. The
mRNA expression rate obtained in ACC non-obese individuals
was assumed as baseline expression level
Bead-based multiplex ELISA
Pro-inflammatory cytokine concentrations (TNFa, IL-6, IL-18,
IL-1b) were assessed in supernatant of 2 mg/ml LPS-stimulated or
unstimulated PBMC isolated from obese individuals carrying
either the ACC or the GTA VDR haplotype (28/group) with the
Bead-based Multiplex method for the Luminex Platform. Super-
natants were obtained following 24-hours LPS stimulation. Cell
cultures were centrifuged for 10 minutes at 300g and supernatants
were collected and stored at -20uC until ELISA quantification.
Plasma LPS Concentration
Plasma LPS concentration was measured in 40 obese subjects
carrying either the ‘‘at-risk’’ (GTA)(N= 20) or the ‘‘protective’’
(ACC)(N= 20) VDR haplotype with the LAL Chromogenic
Endpoint Assay (Hycult biotechnology, Uden, the Netherlands)
according to manufacturer’s instructions. LPS concentration was
calculated in EU/ml and expressed in pg/mL (1EU/ml= 1pg/ml)
and calculated based on a standard curve. Intra and inter-assay
CV were 8.9% and 12.3% respectively.
Statistical Analysis
Data were analyzed using the SPSS version 16.0 (SPSS Inc.,
Chicago, IL, USA). Biochemical parameters were expressed as
mean 6 standard deviation (SD). Independent Student T-test was
used to compare these data in lean and obese subjects. Analysis of
variance (ANOVA) was used to compare different genotypes in
each SNP followed by Dunnett’s Post Hoc test. Linear regression
analysis and analysis of co-variance (ANCOVA) was used to
compare the VDR genotypes adjusted for the co-variants age and
sex. Significance was set at p,0.05. Haplotype frequencies were
estimated by the Expectation-Maximization algorithm (EM
algorithm) implemented in PROC Haplotype in SAS Genetics
statistical software package (SAS institute, Cary, NC, USA). The
standardized measure of linkage disequilibrium (LD), termed r2,
was computed at pairs of SNP loci. Tests of departures from LD
were performed by using the likelihood ratio test (LR test) of
linkage disequilibrium as used in PROC Allele of SAS Genetics.
The most common haplotype was used as the reference and rare
haplotypes were dropped from the analysis.
Supporting Information
Figure S1 Relative expression of the VDR gene in cells of obese
subjects carrying the VDR at ‘‘risk’’ (GTA) or the ‘‘protective’’
(ACC) haplotype. The boxes stretch from the 25th to the 75th
percentile; the lines across the boxes indicate the median values,
those stretching from the boxes indicate extreme values.
(TIF)
VDR Polymorphisms versus Obesity in Saudi
PLOS ONE | www.plosone.org 6 July 2014 | Volume 9 | Issue 7 | e102141
Acknowledgments
The authors are grateful to the staff of the Prince Mutaib Chair for
Biomarkers of Osteoporosis (PMCO) for the technical support.
Author Contributions
Conceived and designed the experiments: NMA FRG. Performed the
experiments: OSA MSA KMA HMD. Analyzed the data: CA ASC IS MB
AKM. Contributed reagents/materials/analysis tools: CA ASC IS MB
AKM. Contributed to the writing of the manuscript: FRG MC.
References
1. World Health Organization (WHO) (2008) [Fact sheet] website. Available:
http://www.who.int/mediacentre/factsheets/fs311/en/print.html. Accessed
2014 Feb 18.
2. Habib SS (2013) Body mass index and body fat percentage in assessment of
obesity prevalence in Saudi adults. Biomed Environ Sci 26: 94–99.
3. Cornelis MC, Hu FB (2012) Gene-environment interactions in the development
of type 2 diabetes: recent progress and continuing challenges. Annu Rev Nutr
32: 245–259.
4. Ritchie SA, Connell JM (2007) The link between abdominal obesity, metabolic
syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis 17: 319–326.
5. Alkharfy KM, Al-Daghri NM, Yakout SM, Hussain T, Mohammed AK, et al
(2013) Influence of vitamin D treatment on transcriptional regulation of insulin-
sensitive genes. Metab Syndr Relat Disord 11: 283–288.
6. Dubois L, Ohm Kyvik K, Girard M, Tatone-Tokuda F, Perusse D, et al. (2012)
Genetic and environmental contributions to weight, height, and BMI from birth
to 19 years of age: an international study of over 12,000 twin pairs. PLoS One 7:
e30153.
7. Ye WZ, Reis AF, Dubois-Laforgue D, Bellanne´-Chantelot C, et al. (2001)
Vitamin D receptor gene polymorphisms are associated with obesity in type 2
diabetic subjects with early age of onset. Eur J Endocrinol 145: 181–186.
8. Schuch NJ, Garcia VC, Martini LA (2009) Vitamin D and endocrine diseases.
Arq Bras Endocrinol Metabol 53: 625–633.
9. Wong KE, Kong J, Zhang W, Szeto FL, Ye H, et al. (2011) Targeted expression
of human vitamin D receptor in adipocytes decreases energy expenditure and
induces obesity in mice. J Biol Chem 286: 33804–33810.
10. Mu¨ller K, Haahr PM, Diamant M, Rieneck K, Kharazmi A, et al. (1992) 1,25-
Dihydroxyvitamin D3 inhibits cytokine production by human blood monocytes
at the post-transcriptional level. Cytokine 4: 506–512.
11. Eleftheriadis T, Antoniadi G, Liakopoulos V, Kartsios C, Stefanidis I, et al.
(2010) Paricalcitol reduces basal and lipopolysaccharide-induced (LPS) TNF-
alpha and IL-8 production by human peripheral blood mononuclear cells. Int
Urol Nephrol 42: 181–185.
12. Yang L, WangJ, Fan Y, Chen S, Wang L, et al (2011) Effect of 1,25(OH)(2)D(3)
on rat peritoneal mesothelial cells treated with high glucose plus lipopolysac-
charide. Cell Immunol 271: 173–179.
13. Marcotorchino J, Gouranton E, Romier B, Tourniaire F, Astier J, et al. (2012)
Vitamin D reduces the inflammatory response and restores glucose uptake in
adipocytes. Mol Nutr Food Res 56: 1771–1782.
14. Suganami T, Ogawa Y (2013) Role of chronic inflammation in adipose tissue in
the pathophysiology of obesity. Nihon Rinsho 71: 225–230.
15. Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP (2004)
Genetics and biology of vitamin D receptor polymorphisms. Gene 338: 143–
156.
16. Ingles SA, Haile RW, Henderson BE, Kolonel LN, Nakaichi G, et al. (1997).
Strength of linkage disequilibrium between two vitamin D receptor markers in
five ethnic groups: implications for association studies. Cancer Epidemiol
Biomarkers Prev 6: 93–98.
17. Dee A, Kearns K, O Neill C, Sharp L, Staines A, et al (2014) The direct and
indirect costs of both overweight and obesity: a systematic review. BMC Res
Notes 7: 242.
18. Roberson LL, Aneni EC, Maziak W, Agatston A, Feldman T, et al (2014)
Beyond BMI: The "Metabolically healthy obese" phenotype & its association
with clinical/subclinical cardiovascular disease and all-cause mortality - a
systematic review. BMC Public Health 14: DOI: 10.1186/1471-2458-14-14.
19. Kramer CK, Zinman B, Retnakaran R. (2013) Are Metabolically Healthy
Overweight and Obesity Benign Conditions? A Systematic Review and Meta-
analysis Ann Int Med. 159: 758–770.
20. Al-Daghri NM, Al-Attas O, Alokail MS, Alkharfy KM, Draz HM, et al. (2012)
Vitamin D receptor gene polymorphisms and HLA DRB1*04 cosegregation in
Saudi type 2 diabetes patients. J Immunol 188: 1325–1332.
21. White JH (2012) Vitamin D metabolism and signaling in the immune system.
Rev Endocr Metab Disord 13: 21–29.
22. Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, et al. (2011)
The NLRP3 inflammasome instigates obesity-induced inflammation and insulin
resistance. Nature Med 17: 179–188.
23. Piya MK, McTernan PG, Kumar S (2013) Adipokine inflammation and insulin
resistance: the role of glucose, lipids and endotoxin. J Endocrinol 216: T1–15.
24. Verdam FJ, Fuentes S, de Jonge C, Zoetendal EG, Erbil R, et al. (2013) Human
intestinal microbiota composition is associated with local and systemic
inflammation in obesity. Obesity (Silver Spring) 21: E607–E615.
25. Rao RK, Seth A, Sheth P (2004) Recent Advances in Alcoholic Liver Disease I.
Role of intestinal permeability and endotoxemia in alcoholic liver disease.
Am J Physiol Gastrointest Liver Physiol 286: G881–884.
26. Harte AL, da Silva NF, Creely SJ, McGee KC, Billyard T, et al. (2010) Elevated
endotoxin levels in non-alcoholic fatty liver disease. J Inflamm (Lond) 7: 15. doi:
10.1186/1476-9255-7-15.
27. Dixon AN, Valsamakis G, Hanif MW, Field A, Boutsiadis A, et al. (2008) Effect
of the orlistat on serum endotoxin lipopolysaccharide and adipocytokines in
South Asian individuals with impaired glucose tolerance. Int J Clin Pract 62:
1124–9.
28. Miller MA, McTernan PG, Harte AL, da Silva NF, Strazzullo P, et al. (2009)
Ethnic and sex differences in circulating endotoxin levels: A novel marker of
atherosclerotic and cardiovascular risk in a British multi-ethnic population.
Atherosclerosis 203: 494–502.
29. Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, et al.
(2011)The NLRP3 inflammasome instigates obesity-induced inflammation and
insulin resistance. Nature Med 17: 179–188.
30. Harte AL, Varma MC, Tripathi G, McGee KC, Al-Daghri NM, et al. (2012)
High fat intake leads to acute postprandial exposure to circulating endotoxin in
type 2 diabetic subjects. Diabetes Care 35: 375–382.
31. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, et al. (2006)
Microbial translocation is a cause of systemic immune activation in chronic HIV
infection. Nature Med 12: 1365–1371.
32. Hofer U, Speck RF (2009) Disturbance of gut-associated lymphoid tissue is
associated with disease progression in chronic HIV infection. Sem Immuno-
pathol 31: 257–266.
33. Piconi S, Trabattoni D, Gori A, Parisotto S, Magni C, et al (2010) Immune
Activation, Apoptosis, and Treg Activity are Associated with Persistently
Reduced CD4+ T Cell Counts during ART. AIDS 24: 1991–2000.
34. Rokholm B, Silventoinen K, Tynelius P, Gamborg M, Sorensen TI, et al (2011)
Increasing genetic variance of body mass index during the Swedish obesity
epidemic. PLoS One 6: e27135.
VDR Polymorphisms versus Obesity in Saudi
PLOS ONE | www.plosone.org 7 July 2014 | Volume 9 | Issue 7 | e102141
